BioSpace News Archive

RadNet, Inc., a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, announced that Mark Stolper, Executive Vice President and Chief Financial Officer, will be presenting at the Sidoti & Company Spring 2021 Conference on Wednesday, March 24th at 01:00 p.m. Eastern Time.

Merger accompanied by £3.8million ($5.3m USD) investment across shareholders, which will be used to fund recruitment and growth of the business

MaaT Pharma announced positive topline results from its Phase 2 clinical trial evaluating lead microbiome ecosystem therapy, MaaT013, in a high-risk patient population with grade III-IV steroid-refractory, gastrointestinal-predominant acute graft-versus-host disease.

T-Cure Bioscience, Inc. announced that the Company has entered into a clinical research agreement with Rutgers, The State University of New Jersey, to fund a Phase I clinical study testing a TCR-based product candidate for the treatment of tumors expressing Kita-Kyushu lung cancer antigen 1, such as gastric, cervical, lung, and triple negative breast cancers.

Dr. Henry Ji will participate in the CEO forum this evening and provide an update on Sorrento’s programs. Sorrento’s Management will be available during the CEO roundtable to answer questions.

Future Planet Capital has invested in a $168m Series B financing announced by Vaccitech Ltd. Future Planet joins other leading investors including M&G Investment Management, Tencent, Gilead Sciences, Monaco Constitutional Reserve Fund and fellow existing investor, Oxford Sciences Innovation.

Sequana Medical NV, an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, announces its financial results for the year ended 31 December 2020, and provides a business update and an outlook for the remainder of 2021.

West Pharmaceutical Services, Inc. announced that management will present virtually at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum at 10:00 AM ET on Wednesday, March 24, 2021.

An article published last week in the Journal of Biomedicine & Pharmacotherapy 111457) presents in vitro evidence for significant inhibition of SARS-CoV-2 by oleandrin and a defined extract of N. oleander, as well as in vivo evidence of the safety and efficacy of PBI-06150.

PRO data further support the monarchE results to date for Verzenio for the treatment of HR+, HER2- high risk early breast cancer